| Quest – Discovery Stage Research Projects | Dr. Alan D. Agulnick | Preclinical development of an immune evasive islet cell replacement therapy for type 1 diabetes |
$1,470,987 |
| Clinical Trial Stage Projects | Manasi Jaiman | Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes |
$13,607,002 |
| Late Stage Preclinical Projects | Dr. Tim Kieffer | Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes |
$3,544,721 |
| Accelerated Development Pathway I | Howard Foyt | Clinical Development of a Cell Therapy for Diabetes |
$8,783,852 |
| Disease Team Planning | Dr. Emmanuel Edward Baetge | Development of a Cell Replacement Therapy Product for Insulin Dependent Diabetes |
$48,950 |
| Strategic Partnership I | Howard Foyt | Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes |
$9,475,070 |
| Early Translational I | Dr. Olivia G. Kelly | Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product |
$5,405,397 |
| Tools and Technologies I | Dr. Evert Kroon | Development of the Theracyte Cellular Encapsulation System for Delivery of human ES Cell-derived Pancreatic Islets and Progenitors. |
$827,072 |
| Disease Team Research I | Allan Robins | Cell Therapy for Diabetes |
$0 |
